6676.TWO Sunny Pharmtech Inc.
- Market cap
- TWD 1.18B
- P/E
- -
- P/B
- 1.64x
- ROE
- -74.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2025.
Is 6676.TWO undervalued?
Graham numberThe Graham number of Sunny Pharmtech Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sunny Pharmtech Inc. fundamental analysis
No fundamental analysis for Sunny Pharmtech Inc. yet.
Sunny Pharmtech Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug formulations and raw materials in Taiwan, the United States, and internationally. It offers lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrof…
Full company profileSunny Pharmtech Inc. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sunny Pharmtech Inc. annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 234M | 420M | 241M | 360M | 429M | 418M | 423M |
| Gross Profit | 95.3M | 224M | 116M | 207M | 286M | 226M | -6.61M |
| Operating Income | -214M | -74.3M | -176M | -188M | -72.1M | -163M | -556M |
| EBITDA | -125M | 10.7M | -64.3M | -54.0M | 69.1M | -23.9M | -339M |
| Net Income | -226M | -102M | -175M | -170M | -63.3M | -156M | -611M |
| EPS | -1.76 | -0.77 | -1.28 | -1.23 | -0.44 | -1.05 | -3.60 |
| Balance Sheet | |||||||
| Total Assets | 1.62B | 1.50B | 1.59B | 1.63B | 1.71B | 1.59B | 1.32B |
| Total Liabilities | 472M | 455M | 468M | 660M | 512M | 541M | 502M |
| Shareholders' Equity | 1.15B | 1.04B | 1.13B | 969M | 1.20B | 1.05B | 819M |
| Cash & Short-term Investments | 337M | 244M | 285M | 290M | 278M | 141M | 91.3M |
| Total Debt | 390M | 385M | 366M | 563M | 391M | 386M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -118M | -26.0M | -34.4M | 26.9M | 38.1M | -37.1M | -384M |
| Capital Expenditure | 78.9M | 68.8M | 161M | 195M | 145M | 49.5M | 38.6M |
| Free Cash Flow | -197M | -94.9M | -195M | -168M | -107M | -86.6M | -423M |
| Ratios | |||||||
| ROE | -19.7% | -9.7% | -15.5% | -17.6% | -5.3% | -14.9% | -74.6% |
| ROA | -14.0% | -6.8% | -11.0% | -10.4% | -3.7% | -9.8% | -46.3% |
| Net Profit Margin | -96.5% | -24.2% | -72.5% | -47.3% | -14.8% | -37.3% | -144.5% |
| Debt to Equity | 0.34x | 0.37x | 0.33x | 0.58x | 0.33x | 0.37x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sunny Pharmtech Inc. dividends
Sunny Pharmtech Inc. has not paid dividends in the last 6 fiscal years.
Who owns Sunny Pharmtech Inc.
Ownership data of Sunny Pharmtech Inc. is not available yet.
Sunny Pharmtech Inc. company profile
- Company name
- Sunny Pharmtech Inc.
- Ticker
- 6676.TWO
- ISIN
- TW0006676000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 160
- Fiscal year end
- December
- Address
- No.255, Longyuan 1st Road, Taoyuan City, Taiwan, 325002
- Phone
- 886 3 480 9168
- Website
- sunnypharmtech.com
About Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug formulations and raw materials in Taiwan, the United States, and internationally. It offers lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; and aminocaproic acid tablets for blood diseases and hyper-proteolytic enzymes. It also provides carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases. The company was founded in 2014 and is based in Taoyuan City, Taiwan.
Sunny Pharmtech Inc. management
4- Dr. Yon-Lian WuFounder, CEO & Chairman
- Mr. Kun-Hung TsaiCFO & Accounting Supervisor
- Ms. Yung-Yi ChenVice President of Operations
- Ms. Lun-Yin ChouVice President of Legal